Nonprofit Pushes for US Bill to End Wait for Patient Benefits

Nonprofit Pushes for US Bill to End Wait for Patient Benefits

U.S. lawmakers have again introduced legislation that would speed up the process for Huntington’s disease (HD) patients to get Medicare and Social Security Disability Insurance (SSDI) benefits. The Huntington’s Disease Disability Insurance Access Act of 2021 — S 868/ HR 2050 — would waive the mandatory two-year…

Time Flies When You Want It to Slow Down

This week, my wife, Jill, bought meals from HelloFresh, a company that sells kits with the ingredients and the recipes to cook at home. Apparently, because of the pandemic, something known as “cooking fatigue” has led many people to tire of the repetitive chore of starting from scratch.

GENERATION HD1 Trial Fails to Show Benefits of Tominersen

Treatment with tominersen failed to show evidence of clinical benefit in adults with Huntington’s disease during the Phase 3 clinical trial GENERATION HD1. Roche, the company developing tominersen, decided to pause dosing in the clinical trial about a month ago, after a pre-planned review of trial data…

The Importance of Preserving Our Words

I recently received an email from Kelli Yoder, the communications manager at Adira Foundation, an organization whose mission is to “invest in better lives for people with neurodegenerative diseases.” She wrote that the foundation had enlisted the help of StoryCorps, a…

How the HEATED Project Can Benefit the Huntington’s Community

As I wrote in a previous column titled, “An Abundance of Huntington’s Disease Info Awaits at Upcoming Virtual Conferences,” there are many ways to learn about the latest and greatest happenings in the HD community. I attended last month’s Huntington’s Disease Youth Organization’s International Young Adult Virtual Congress,…

FDA Gives Go-ahead for Phase 1/2 Trial Testing VY-HTT01 Gene Therapy

The U.S. Food and Drug Administration (FDA) has granted Voyager Therapeutics permission to start a clinical trial testing VY-HTT01, its investigational gene therapy for Huntington’s disease. Voyager is planning to launch the Phase 1/2 clinical trial, called VYTAL, later this year. VYTAL will be a dose-escalation study, meaning that…